Literature DB >> 33326100

Drug Screening by Resazurin Colorimetry in Ewing Sarcoma.

Julian Musa1,2,3,4, Florencia Cidre-Aranaz5,6,7.   

Abstract

In Ewing sarcoma (EwS), development of new therapeutic strategies is crucial in order to refine treatment and improve patient survival, especially in metastatic or recurrent disease stages. Thus, preclinical drug screening is a key issue in EwS research. As especially in such drug screening assays, the cell viability aspect of cell proliferation is important, resazurin colorimetry shall be reviewed here as a fast, high-throughput method with automated readout to efficiently screen for potency of drugs via measurement of cell viability.

Entities:  

Keywords:  Cell viability; Drug screening; Ewing sarcoma; Resazurin

Mesh:

Substances:

Year:  2021        PMID: 33326100     DOI: 10.1007/978-1-0716-1020-6_12

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  10 in total

1.  Research Techniques Made Simple: Techniques to Assess Cell Proliferation.

Authors:  George A Romar; Thomas S Kupper; Sherrie J Divito
Journal:  J Invest Dermatol       Date:  2016-01       Impact factor: 8.551

2.  Basic Colorimetric Proliferation Assays: MTT, WST, and Resazurin.

Authors:  Konstantin Präbst; Hannes Engelhardt; Stefan Ringgeler; Holger Hübner
Journal:  Methods Mol Biol       Date:  2017

3.  Metabolic reduction of resazurin; location within the cell for cytotoxicity assays.

Authors:  Jian Lin Chen; Terry W J Steele; David C Stuckey
Journal:  Biotechnol Bioeng       Date:  2017-11-09       Impact factor: 4.530

Review 4.  Ewing sarcoma.

Authors:  Thomas G P Grünewald; Florencia Cidre-Aranaz; Didier Surdez; Eleni M Tomazou; Enrique de Álava; Heinrich Kovar; Poul H Sorensen; Olivier Delattre; Uta Dirksen
Journal:  Nat Rev Dis Primers       Date:  2018-07-05       Impact factor: 52.329

5.  Assessment of cell proliferation with resazurin-based fluorescent dye.

Authors:  Ewa M Czekanska
Journal:  Methods Mol Biol       Date:  2011

Review 6.  50 years of preclinical anticancer drug screening: empirical to target-driven approaches.

Authors:  Marie Suggitt; Michael C Bibby
Journal:  Clin Cancer Res       Date:  2005-02-01       Impact factor: 12.531

7.  Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite.

Authors:  Thomas G P Grünewald; Virginie Bernard; Pascale Gilardi-Hebenstreit; Virginie Raynal; Didier Surdez; Marie-Ming Aynaud; Olivier Mirabeau; Florencia Cidre-Aranaz; Franck Tirode; Sakina Zaidi; Gaëlle Perot; Anneliene H Jonker; Carlo Lucchesi; Marie-Cécile Le Deley; Odile Oberlin; Perrine Marec-Bérard; Amélie S Véron; Stephanie Reynaud; Eve Lapouble; Valentina Boeva; Thomas Rio Frio; Javier Alonso; Smita Bhatia; Gaëlle Pierron; Geraldine Cancel-Tassin; Olivier Cussenot; David G Cox; Lindsay M Morton; Mitchell J Machiela; Stephen J Chanock; Patrick Charnay; Olivier Delattre
Journal:  Nat Genet       Date:  2015-07-27       Impact factor: 38.330

8.  EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma.

Authors:  F Cidre-Aranaz; T G P Grünewald; D Surdez; L García-García; J Carlos Lázaro; T Kirchner; L González-González; A Sastre; P García-Miguel; S E López-Pérez; S Monzón; O Delattre; J Alonso
Journal:  Oncogene       Date:  2016-07-04       Impact factor: 9.867

9.  Targeting the CALCB/RAMP1 axis inhibits growth of Ewing sarcoma.

Authors:  Marlene Dallmayer; Jing Li; Shunya Ohmura; Rebeca Alba Rubio; Michaela C Baldauf; Tilman L B Hölting; Julian Musa; Max M L Knott; Stefanie Stein; Florencia Cidre-Aranaz; Fabienne S Wehweck; Laura Romero-Pérez; Julia S Gerke; Martin F Orth; Aruna Marchetto; Thomas Kirchner; Horacio Bach; Giuseppina Sannino; Thomas G P Grünewald
Journal:  Cell Death Dis       Date:  2019-02-11       Impact factor: 8.469

10.  Cooperation of cancer drivers with regulatory germline variants shapes clinical outcomes.

Authors:  Julian Musa; Florencia Cidre-Aranaz; Marie-Ming Aynaud; Martin F Orth; Maximilian M L Knott; Olivier Mirabeau; Gal Mazor; Mor Varon; Tilman L B Hölting; Sandrine Grossetête; Moritz Gartlgruber; Didier Surdez; Julia S Gerke; Shunya Ohmura; Aruna Marchetto; Marlene Dallmayer; Michaela C Baldauf; Stefanie Stein; Giuseppina Sannino; Jing Li; Laura Romero-Pérez; Frank Westermann; Wolfgang Hartmann; Uta Dirksen; Melissa Gymrek; Nathaniel D Anderson; Adam Shlien; Barak Rotblat; Thomas Kirchner; Olivier Delattre; Thomas G P Grünewald
Journal:  Nat Commun       Date:  2019-09-11       Impact factor: 14.919

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.